Abiraterone    (DrugBank: Abiraterone)

2 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease1
81Congenital adrenal hyperplasia3

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 191 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03145285
(ClinicalTrials.gov)
April 18, 201726/4/2017Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaActivity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaCushing Syndrome;Adrenocortical CarcinomaDrug: Abiraterone AcetateAzienda Ospedaliera Spedali Civili di BresciaFondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga HospitalActive, not recruiting18 YearsN/AAll10Phase 2Italy

81. Congenital adrenal hyperplasia    [ 65 clinical trials,   77 drugs,   (DrugBank: 20 drugs),   11 drug target genes,   65 drug target pathways]
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 65 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03548246
(ClinicalTrials.gov)
January 202224/4/2015Androgen Reduction in Congenital Adrenal HyperplasiaA Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyCongenital Adrenal HyperplasiaDrug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: FludrocortisoneUniversity of Texas Southwestern Medical CenterNational Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical ResearchNot yet recruiting2 Years9 YearsAll54Phase 2United States
2NCT02574910
(ClinicalTrials.gov)
August 1, 201724/4/2015Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyCongenital Adrenal HyperplasiaDrug: Abiraterone acetateUniversity of Texas Southwestern Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);University of Michigan;Children's Hospital Los AngelesActive, not recruiting2 Years9 YearsAll36Phase 1United States
3NCT01495910
(ClinicalTrials.gov)
December 201123/11/2011A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase DeficiencyAn Open-Label, Multiple-Dose, Dose-Finding Study of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency21-hydroxylase DeficiencyDrug: Abiraterone acetateJohnson & Johnson Pharmaceutical Research & Development, L.L.C.NULLCompleted18 YearsN/AFemale6Phase 1United States